Repros Therapeutics Inc (NASDAQ:RPRX)

During the Trading Day
15.98 +0.28 / +1.78%
Data as of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
15.98 0.00 / 0.00%
Volume: 931.00
Health Technology
Medical Specialties

Company Description

epros Therapeutics Inc. is a development stage biopharmaceutical company focused on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders. The company's current product pipeline consist, Androxal, Proellex, Vasomax and Z-Max. Repros Therapeutics was founded on August 28, 1987 and is headquartered in the Woodlands, TX.

Contact Information

Repros Therapeutics, Inc.
2408 Timberloch Place
Woodlands Texas 77380
P:(281) 719-3400
Investor Relations:



Individual stakeholders9.65%
Other institutional85.08%
Mutual fund holders27.82%

Top Executives

Joseph S. PodolskiPresident, Chief Executive Officer & Director
Katherine A. AndersonSecretary, Chief Financial & Accounting Officer
Ronald D. WiehleVice President-Research & Development
Jaye L. ThompsonSenior Vice President-Clinical & Regulatory
Joachim F. WernickeChief Medical Officer

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.